150 related articles for article (PubMed ID: 37649865)
1. Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B.
Ishido S; Tamaki N; Uchihara N; Suzuki K; Tanaka Y; Miyamoto H; Yamada M; Matsumoto H; Nobusawa T; Keitoku T; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Takahashi Y; Tsuchiya K; Nakanishi H; Itakura J; Kurosaki M; Izumi N
JGH Open; 2023 Aug; 7(8):567-571. PubMed ID: 37649865
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia].
Liu LP; Wu XP; Cai TP; Wang L; Sun J; Liang JY; Ma SP; Gan X; Ruan NH; Ge SF
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):118-125. PubMed ID: 37137825
[No Abstract] [Full Text] [Related]
3. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Li ZB; Li L; Niu XX; Chen SH; Fu YM; Wang CY; Liu Y; Shao Q; Chen G; Ji D
Liver Int; 2021 Jun; 41(6):1254-1264. PubMed ID: 33404182
[TBL] [Abstract][Full Text] [Related]
4. Long-term health and economic benefits of switching to tenofovir alafenamide versus continuing on entecavir in chronic hepatitis B patients with low-level viremia in Saudi Arabia.
Sanai FM; Aljawad M; Alghamdi AS; Yehoshua A; Khathlan A; Alghamdi M; Kozma S; Smith N; El-Moustaid F; Jeyakumar S; Kachru N
Saudi J Gastroenterol; 2024 Jan; 30(1):23-29. PubMed ID: 37417192
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir.
Yuan GC; Chen AZ; Wang WX; Yi XL; Tu L; Peng F; Qiu ZH
World J Clin Cases; 2023 Dec; 11(34):8139-8146. PubMed ID: 38130795
[TBL] [Abstract][Full Text] [Related]
6. Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir.
Sato K; Inoue J; Akahane T; Kobayashi T; Takai S; Nakamura T; Sato T; Kimura O; Ninomiya M; Iwata T; Sano A; Tsuruoka M; Onuki M; Sawahashi S; Niitsuma H; Masamune A
Tohoku J Exp Med; 2022 Nov; 258(4):277-285. PubMed ID: 36244758
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J;
Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611
[TBL] [Abstract][Full Text] [Related]
8. Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA.
Yamada S; Uchida Y; Kouyama JI; Naiki K; Tsuji S; Uemura H; Sugawara K; Nakayama N; Imai Y; Tomiya T; Mizuno S; Mochida S
Hepatol Res; 2024 Mar; ():. PubMed ID: 38517681
[TBL] [Abstract][Full Text] [Related]
9. Sequential therapy from entecavir to tenofovir alafenamide
Itokawa N; Atsukawa M; Tsubota A; Takaguchi K; Nakamuta M; Hiraoka A; Kato K; Abe H; Mikami S; Shimada N; Chuma M; Akito N; Uojima H; Ogawa C; Asano T; Tani J; Morishita A; Senoh T; Yamashita N; Oikawa T; Matsumoto Y; Koeda M; Yoshida Y; Tanabe T; Okubo T; Arai T; Hayama K; Iwashita AN; Kondo C; Tada T; Toyoda H; Kumada T; Iwakiri K
JGH Open; 2021 Jan; 5(1):34-40. PubMed ID: 33490611
[TBL] [Abstract][Full Text] [Related]
10. Comparison of tenofovir alafenamide and entecavir for hepatitis B virus
Peng W; Gu H; Jiang C; Liu J; Zhang J; Fu L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):194-201. PubMed ID: 35545409
[TBL] [Abstract][Full Text] [Related]
11. Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Uchida Y; Nakao M; Tsuji S; Uemura H; Kouyama JI; Naiki K; Motoya D; Sugawara K; Nakayama N; Imai Y; Tomiya T; Mochida S
J Med Virol; 2020 Mar; 92(3):329-338. PubMed ID: 31777965
[TBL] [Abstract][Full Text] [Related]
12. Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study.
Sato K; Inoue J; Akahane T; Kobayashi T; Sato S; Kisara N; Ninomiya M; Iwata T; Sano A; Tsuruoka M; Onuki M; Masamune A
Medicine (Baltimore); 2022 Sep; 101(39):e30630. PubMed ID: 36181074
[TBL] [Abstract][Full Text] [Related]
13. Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
Uchida Y; Nakao M; Yamada S; Tsuji S; Uemura H; Kouyama JI; Naiki K; Sugawara K; Nakayama N; Imai Y; Tomiya T; Mochida S
PLoS One; 2022; 17(2):e0262764. PubMed ID: 35180213
[TBL] [Abstract][Full Text] [Related]
14. Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
Kumada T; Toyoda H; Yasuda S; Ito T; Tanaka J
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e898-e904. PubMed ID: 35048656
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy.
Lee IC; Lan KH; Su CW; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232631
[TBL] [Abstract][Full Text] [Related]
16. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
17. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
Hepatol Int; 2021 Oct; 15(5):1083-1092. PubMed ID: 34402025
[TBL] [Abstract][Full Text] [Related]
18. Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.
Hagiwara S; Nishida N; Ida H; Ueshima K; Minami Y; Takita M; Komeda Y; Kudo M
J Med Virol; 2019 Oct; 91(10):1804-1810. PubMed ID: 31199513
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir.
Tamaki N; Kurosaki M; Kirino S; Yamashita K; Osawa L; Sekiguchi S; Hayakawa Y; Wang W; Okada M; Higuchi M; Takaura K; Maeyashiki C; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Enomoto N; Izumi N
JGH Open; 2020 Jun; 4(3):429-432. PubMed ID: 32514449
[TBL] [Abstract][Full Text] [Related]
20. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y
BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
